According to the previous data, YAP1 served as an oncogene in GC, and targeting YAP1 was effective to restrain cancer progression [37–39], which were supported by our data that YAP1 was high-expressed in GC tissues and cells, and GC patients with high-expressed were prone to have a worse prognosis. Here, YAP1 is linked to gastric cancer.